Hypertension in adult polycystic kidney disease: a narrative review

被引：0

作者：

Mian, Sarah ^{[1
]}

Acharya, Yogesh ^{[1
]}

Dahal, Ranjan ^{[2
]}

机构：

[1] Avalon Univ, Sch Med, Curacao, Neth Antilles

[2] St Peters Univ Hosp, New Brunswick, NJ 08901 USA

来源：

JOURNAL OF RENAL INJURY PREVENTION | 2019年 / 8卷 / 02期

关键词：

Adult polycystic kidney disease; Hypertension; Antihypertensive agents; Prevention and control; Renin-angiotensin-aldosterone system; End stage renal disease; Glomerular filtration rate; Chronic kidney disease; CONVERTING-ENZYME-INHIBITORS; BLOOD-PRESSURE; ENDOTHELIN; PROGRESSION; ADPKD;

D O I：

10.15171/jrip.2019.23

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited renal disorder that impacts approximately 12 million worldwide. It is characterized by bilateral kidney enlargement and cystic growth. Hypertension (HTN) is a focal point in the management of ADPKD and is linked to a faster progression to end stage renal disease. Current novel therapies have proven to reduce the progression of renal damage. The ideal goal is to minimize risk through preventative studies and pharmacology to further increase life expectancy and quality. The purpose of this article is to highlight the importance of blood pressure management in ADPKD and review current literature to determine the most effective preventative pharmacotherapy.

引用

页码：122 / 126

页数：5

共 50 条

[21] Endothelin in Polycystic Kidney Disease
Chang, Ming-Yang
Ong, Albert C. M.
ENDOTHELIN IN RENAL PHYSIOLOGY AND DISEASE, 2011, 172 : 200 - 209
[22] Hypertension in Children with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Cadnapaphornchai, Melissa A.
CURRENT HYPERTENSION REVIEWS, 2013, 9 (01) : 21 - 26
[23] Hypertension in Autosomal Dominant Polycystic Kidney Disease
Chapman, Arlene B.
Stepniakowski, Konrad
Rahbari-Oskoui, Frederic
ADVANCES IN CHRONIC KIDNEY DISEASE, 2010, 17 (02) : 153 - 163
[24] Polycystic Kidney Disease Presenting With Hypertension and Hypokalemia
Chow, Kai Ming
Ma, Ronald Ching-Wan
Szeto, Cheuk Chun
Li, Philip Kam-Tao
AMERICAN JOURNAL OF KIDNEY DISEASES, 2012, 59 (02) : 270 - 272
[25] Diet and polycystic kidney disease: A pilot intervention study
Taylor, Jacob M.
Hamilton-Reeves, Jill M.
Sullivan, Debra K.
Gibson, Cheryl A.
Creed, Catherine
Carlson, Susan E.
Wesson, Donald E.
Grantham, Jared J.
CLINICAL NUTRITION, 2017, 36 (02) : 458 - 466
[26] Recognizing and treating autosomal dominant polycystic kidney disease
Uko, Chigozie G.
NURSE PRACTITIONER, 2020, 45 (11) : 41 - 47
[27] Autosomal dominant polycystic kidney disease: updated perspectives
Rastogi, Anjay
Ameen, Khalid Mohammed
Al-Baghdadi, Maha
Shaffer, Kelly
Nobakht, Niloofar
Kamgar, Mohammad
Lerma, Edgar, V
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2019, 15 : 1041 - 1052
[28] Pathogenesis and treatment of hypertension in polycystic kidney disease
Neumann, J
Ligtenberg, G
Klein, IHHT
Blankestijn, PJ
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (05) : 517 - 521
[29] A renaissance in the treatment of diabetic kidney disease, hypertension in chronic kidney disease, and beyond
Yahr, Jordana
Calle, Juan
Taliercio, Jonathan J.
JOURNAL OF OSTEOPATHIC MEDICINE, 2021, 122 (01): : 55 - 63
[30] HYPERTENSION IN AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE (ADPKD)
ZEIER, M
MANDELBAUM, A
NIEREN-UND HOCHDRUCKKRANKHEITEN, 1993, 22 (09) : 455 - 458

← 1 2 3 4 5 →